Markets

Markets Overview Market Context

Briefs Calendar

Research

News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive

LIVECAST Markets

☀◐Theme

Menu

Home LIVECAST Markets Market Context Briefs Calendar News Search AI Market Assistant Charts & News Instrument directory Macro Politics Prediction Markets News Archive Account

Home News ArchiveSilence Therapeutics Agrees to Be Acquired by Merck KGaA

Live News MNA FLASH M impact Oct 19, 2026, 12:00 PM UTC

Silence Therapeutics Agrees to Be Acquired by Merck KGaA

SquawkNews Desk

Use this page

Share or save this market-moving headline as a permanent SquawkNews URL. The live feed continues at /news.

Open live news feed Browse news archive Browse news categories Search related coverage

Related tickers

SLN

Related stories

Silgan to Combine Metal Packaging Business With Trivium in $2.3 Billion Deal Silgan announced an agreement to combine its metal packaging business with Trivium Packaging, delivering $2.3 billion in cash proceeds. Silgan shares rose 5.1% in morning trading. M impact | MNA | Oct 19, 2026, 02:33 PM UTC Merck KGaA to Acquire Silence Therapeutics in All-Cash Deal Silence Therapeutics said it agreed to be purchased by Germany's Merck KGaA in an all-cash deal for its gene-silencing technology. The headline states Merck is paying a 130% premiu M impact | EQUITY | Oct 19, 2026, 02:19 PM UTC Multiconsult Shareholders Approve Merger With Rejlers Multiconsult ASA said its extraordinary general meeting approved all agenda items as proposed, including the merger with Rejlers AB. M impact | MNA | Oct 19, 2026, 01:54 PM UTC Red Cat Plans to Buy Steyr Motors for EUR39 Per Share Red Cat announced plans to acquire Steyr Motors for EUR39 ($43.73) per share, valuing the company at about $250 million. Steyr is expected to generate roughly $100 million in 2027 M impact | MNA | Oct 19, 2026, 01:49 PM UTC Merck KGaA to acquire Silence Therapeutics for about $1.3 billion Merck KGaA said it will acquire Silence Therapeutics in an all-cash deal valued at about $1.3 billion. M impact | EQUITY | Oct 19, 2026, 01:43 PM UTC Roche and Hansoh Sign Cancer Drug Licensing Deal Worth Up to $15 Billion Roche entered a collaboration and licensing agreement with China's Hansoh for a portfolio of targeted cancer drugs. The deal could exceed $15 billion. M impact | MNA | Oct 19, 2026, 01:38 PM UTC

SQUAWK/NEWS

Independent financial newsroom. Editorial expertise and proprietary AI. Paid LiveCast brings live headlines, chart context and priority audio to your trading day. Free research tools remain available.

LiveCast passes from $15 · Institutional API access.

Start LiveCast

News & Research

Open LiveCast
Session Briefs
Market Context
Macro
Politics
Prediction Markets
News Archive

Markets & Tools

Charts & News
Markets Overview
US Stocks
Market Movers
Economic Calendar
Policy Calendar
AI Market Assistant
News Search
Instrument Directory

Guides

Charts & News Guide
How LiveCast Works
What Is an Audio Squawk?
Why News Moves Markets
News for Traders
How to Trade the News

Plans & API

Plans & Pricing
Institutional API
RSS Feed

Company

About
Why SquawkNews
Newsroom
Editorial Standards
Corrections
Contact us

© 2026 SquawkNews

Privacy Policy Terms of Use

SquawkNews publishes market information and context. It does not provide investment advice or trade recommendations.